On May 16, 2018 MEI Pharma, Inc. (NASDAQ: MEIP), a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, reported the publication of two data abstracts related to MEI Pharma’s clinical stage drug development programs to be presented at the 2018 ASCO (Free ASCO Whitepaper) Annual Meeting to be held June 1-5, 2018 in Chicago (Press release, MEI Pharma, MAY 16, 2018, View Source [SID1234526708]). Study investigators will present updated results from the Phase 1b study evaluating ME-401 in relapsed/refractory indolent B-cell malignancies and from an investigator-initiated study of ME-344 in patients with HER2-negative breast cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The ASCO (Free ASCO Whitepaper) Annual Meeting is an important event for MEI Pharma this year and we are excited to present promising updated data from both our ME-401 and ME-344 programs at the meeting next month," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "Specifically with regard to the ME-401 program, the Phase 1b data demonstrating high efficacy rates across all patient groups with an adverse event profile consistent with other PI3K delta inhibitors, along with our recently announced financing, make us well positioned to pursue our plan to initiate a ME-401 registration study before year end."
Poster Presentations at ASCO (Free ASCO Whitepaper) 2018
Title: Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Date & Time: 6/4/2018, 1:15 PM-2:30 PM
Poster Discussion Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract: 7519
Author: Jacob Drobnyk Soumerai, M.D., Massachusetts General Hospital
Title: Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME-344 or placebo in early HER2-negative breast cancer (HERNEBC).
Date & Time: 6/4/2018, 8:00 AM-11:30 AM
Poster Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Abstract: 2552
Author: Miguel Quintela-Fandino, M.D., Ph.D., Director of the Clinical Research Program, Centro Nacional De Investigaciones Oncologicas, Madrid, Spain.
Abstracts featured as part of the ASCO (Free ASCO Whitepaper) 2018 program may be found at: View Source